Bronchogen vs Thymalin
A side-by-side research comparison of Bronchogen and Thymalin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Bronchogen | Thymalin |
|---|---|---|
| Full name | Bronchogen (Ala-Asp-Glu-Leu Bronchopulmonary Bioregulator) | Thymalin (Thymus Extract Peptide) |
| Category | Immune Support | Immune Support |
| Status | Research compound (peptide bioregulator) | Research compound |
| Mechanism | As a signal peptide (Ala-Asp-Glu-Leu), it is proposed to regulate gene expression in respiratory epithelial tissue, supporting airway lining integrity, antioxidant defense, and local respiratory immune function. | Contains bioactive thymic peptides that regulate T-lymphocyte differentiation, restore T-helper/T-suppressor ratios, and enhance phagocyte activity and interferon production. |
| Molecular weight | ~445 Da | ~1000-5000 Da (complex mixture) |
| Half-life | Short (peptide) | ~4-6 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~80% intramuscular |
| Typical dose | ~1-2 capsules/day or short injectable courses | 5-10 mg |
| Frequency | Once daily | Daily for 5-10 days |
| Route | Oral capsule or subcutaneous | Intramuscular injection |
Bronchogen reported benefits
- Respiratory/airway support
- Bronchopulmonary tissue maintenance (proposed)
- Local respiratory immune support
- Short course-based protocol
Thymalin reported benefits
- Immune reconstitution
- T-cell ratio normalization
- Interferon production
- Anti-tumor immunity support
Related comparisons
Research and educational reference only. Not medical advice.